J&J Unit Sues Mylan to Block Copies of Schizophrenia Treatment

J&J’s Janssen said Mylan’s proposed generic version of an extended-release injectable treatment for schizophrenia infringes a patent for Invega Trinza.

• J&J is seeking a court order blocking copies until the patent has expired, and cash compensation if copies are made before then, according to complaint filed Wednesday in federal court in Trenton, New Jersey
• Trinza is a quarterly injectable of Invega Sustenna, which is dosed monthly
• Patent expires in April 2036: FDA Orange Book
• Invega Sustenna and Trinza had U.S. sales of $1.12 billion during the first half of 2020, up by 13.2% from the same period in ...